BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Its core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Its business approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.
BioLargo Inc. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page.
Please refer to the important disclosures below for additional details.
The company's Pooph line of pet odor eliminating products "continues to experience strong commercialization growth," noted an Oak Ridge Financial Research report.
Clean technology company BioLargo Inc. (BLGO:OTCQX) continues to see rising revenues with strong year-over-year and quarter-over-quarter growth. Find out why one analyst recommends investors look at the stock.
Clean technology company BioLargo Inc. (BLGO:OTCQX) announces preliminary financial results for the second quarter ending June 30, 2024, including a 247% increase in revenue QoQ. One analyst says the stock is headed for an upleg.
So-called "forever chemicals" used by industry in water and food are becoming more ubiquitous worldwide, researchers said, even in lithium-ion batteries powering the energy transition. One company has solutions.
With Electric Vehicles (EVs) and a swarm of new products requiring more power, experts agree that a surge in demand is coming, and soon. Here are several companies that can get you exposure to this important and growing resource.
Research is showing that more of us and more parts of us are being exposed to so-called "forever chemicals." BioLargo Inc. (BLGO:OTCQB) said its technology removes 99% of them.
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic.
Clean technology company BioLargo Inc. (BLGO:OTCQB) announced it has manufactured its "liquid sodium" prototype battery cells that it says are long-lasting and safer than lithium-ion batteries. One technical analyst said the stock is a great spot to buy.
Clean tech company BioLargo Inc. (BLGO:OTCQB) announced its engineering subsidiary has been awarded a contract to provide air quality services at three New Mexico U.S. Air Force bases. The company is also seeing success with its pet odor control product and its solution to treat so-called "forever chemicals."
New research is revealing more bad news about just how far "forever chemical" pollution reaches in North America, pointing to an even bigger need for technology like BioLargo Inc.'s treatment systems for removing them.
BioLargo Inc. announced record quarterly revenues of US$4.76 million for the three months ending March 31, a 28% increase over the first quarter of 2023. Find out why one analyst sees a bull market coming for the company.
As the U.S. federal government continues to crackdown on so-called "forever chemicals," one company said its technology could help localities comply with the regulations. One technical analyst is predicting a breakout in the company's stock.
Utilities could use this technology, which reduces PFAS in water, to meet the new standards for public drinking water, noted an Oak Ridge Financial report.
BioLargo Inc. may be uniquely positioned to take advantage of new U.S. federal drinking water standards announced Wednesday meant to limit exposure to so-called "forever chemicals." Find out why one technical analyst says this stock is headed for a bull market.
The controversy over dangerous PFAS, also known as "forever chemicals," has hit two small farms in Texas. Find out why one analyst thinks a company with a solution is headed for a bull market as its stock rises.
Almost half of the nation's tap water is affected by so-called "forever chemicals." Find out if these dangerous substances have been found in waters near you.
By hiring the longest-serving CEO of the Metropolitan Water District of Southern California, BioLargo, Inc. has positioned itself as a leader of a nascent industry.
Clean tech company BioLargo Inc. is launching a new subsidiary to capitalize on its treatment technologies ridding water of so-called "forever chemicals." One analyst says the pipeline of potential projects is growing.
The potential stock-boosting events for this U.S. company include product launches, an inked partnership and revenue generation. Read more about them here.
You've been hearing plenty about the importance and scarcity of lithium for powering electric vehicles (EVs) in the battle to stop climate change. But another, humbler, element may also be on the table: Salt.
Technical Analyst Clive Maund takes a look at BioLargo Inc.'s 20-year, 19-month, and 6-month charts to explain why he believes a new bull market may be incubating for this clean tech company.
More than 200 million Americans could have harmful "forever chemicals" in their drinking water, and this clean tech company says 99% of them can be removed by its technology.
BioLargo Inc.'s hit pet odor control product Pooph is launching at more than 20,000 stores this year, a tenfold increase in its current retail store count. The company also announced a 127% increase in year-to-date revenues compared to the last period. Read to see the press release, and what catalysts Biolargo sees coming its way.
This clean tech company's approach to addressing everything from "forever chemicals" in the environment to stubborn pet odors is about to payoff, an analyst says.
BioLargo Inc.'s pet odor control product, Pooph, is "taking the market by storm." Find out how this company is a 'Strong Buy,' according to one analyst.
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news.
Shares of this green technology company have bottomed out, making it a good time to buy back any positions sold or add to existing ones, analyst Clive Maund says.
Chris Temple of The National Investor explains why he has issued a speculative buy recommendation for BioLargo, a small-cap company with a flagship product that removes certain contaminants from water.
In an article for Streetwise Reports, Penny Queen explains how environmental engineering company, BioLargo Inc., is on track to "make shareholders' portfolios better."
"BioLargo Inc. delivered 247% year-over-year revenue growth in Q2/24, ahead of our estimates. Pooph revenue continues to grow rapidly, and the company's first PFAS remediation project is on track for completion by Q4/24. We are bullish on BioLargo's long-term prospects."
Richard Ryan, Oak Ridge Financial
(8/16/24)
"BioLargo Inc. announced Q2/24 revenues that again showed strong year-over-year and modest quarter-over-quarter growth. Revenues were $5M, up from $1.4M a year ago and up 5% sequentially as Pooph sales saw continued good performance."
Richard Ryan, Oak Ridge Financial
(5/16/24)
"BioLargo Inc. announced Q1/24 revenues that again showed strong year-over-year and quarter-over-quarter growth. The company generated positive cash flow from operations and increased its shareholders' equity to $5.1M, all while maintaining minimal debt and ending the quarter with $4.3M in cash."
Richard Ryan, Oak Ridge Financial
(4/17/24)
"The final PFAS regulations from the Environmental Protection Agency validate BioLargo Inc.'s water treatment vision. . .under the new rule, water utilities must monitor PFAS chemicals and would be required to notify the public and reduce contamination if levels exceeded the new standard. . .the large emerging market for PFAS removal and the company's growing validation in this opportunity should not be overlooked."
Richard Ryan, Oak Ridge Financial
(4/4/24)
"BioLargo Inc. announced that 2023 revenues more than doubled the level the company reported in 2022, making it the second year in a row that revenues have grown at that rate. BioLargo maintained gross margin at 50%, doubled shareholders' equity, all while maintaining minimal debt and ending the year with $3.5M in cash."
Clive Maund, CliveMaund.com
(2/14/24)
"The fundamentals of BioLargo Inc. are superb with everything coming together in a positive manner after many years of work. So ultimately, the company's stock is believed headed much higher."
More Expert Comments
Richard Ryan, Oak Ridge Financial
(1/29/24)
"BioLargo Inc. announced that its 2023 revenues more than doubled the level it reported in 2022, making it the second year in a row that revenues have grown at that rate. . .the company's results continue to be driven by Pooph sales, its pet odor control product line that is being sold through national retailers like Amazon, Walmart, Chewy and a growing list of other retailers."
Clive Maund, CliveMaund.com
(1/25/24)
"Over the past couple of days after a steep advance, BioLargo Inc. has reacted back a shade. But the dramatic dieback in volume is bullish and suggests that this steep uptrend is not done yet."
Clive Maund, CliveMaund.com
(12/22/23)
"BioLargo Inc. is at a good entry point here, and the company is rated a Strong Conservative Buy for all time frames. . .it is considered to have substantial upside from here with the capacity to make faster gains than many consider possible, especially if there is anything to the sodium battery story."
Richard Ryan, Oak Ridge Financial
(12/8/23)
"BioLargo Inc. has finished its rollout of Pooph into Walmart locations and expects that Ikigai, its major distribution partner, can secure contracts for more than 20K retail stores by 2023E. . .Pooph appears to be on the cusp for significant revenue expansion, which has been reaffirmed through Amazon as Pooph averages over 90K bottles purchased each month (as of Dec. 7, 2023) with a Best Seller ranking of No. 1 in Dog Deodorizers."
Chris Temple, Editor and Publisher– The National Investor
Company News
8/13/2024 – BioLargo Earnings Results Webcast and Conference Call on Wednesday, August 14, 2024 - 1:30 PM Pacific Time
8/6/2024 – BioLargo Achieves Record Quarterly Revenue of $5 Million for Second Quarter of 2024
6/20/2024 – BioLargo Engineering Increases Ongoing Revenue with Another Air Force Contract
6/12/2024 – BioLargo Subsidiary Clyra Medical Selects Keystone Industries to Support Manufacturing of its Medical Products
6/11/2024 – BioLargo Manufactures First Cellinity Battery Cells, a Safer Alternative to Lithium-ion
6/7/2024 – BioLargo Engineering Secures Multi-Year Air Force Base Air Compliance Project
5/10/2024 – BioLargo Q1 2024 Earnings Results Webcast and Conference Call on Tuesday, May 14, 2024 - 5:30 PM Eastern Time
Important Disclosures
BioLargo Inc. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases.
The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content.
Billboard advertising monthly fees range from $3,000 to $5,000.
This landing page contains a summary of the company that was prepared by that company.
Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company.
The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports.
There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page.
Readers should conduct their own research for all information publicly available concerning the company.
This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.